Who Owns Climb Bio Stock?
NASDAQ: CLYMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 117.94%
- Institutions (% of float)
- 118.15%
- Held by insiders
- 0.17%
- Institutional holders
- 173
- Institutions 99.8%
- Insiders 0.2%
- Public and other 0.0%
Who owns Climb Bio stock?
Institutional investors own about 117.9% of Climb Bio's shares, spread across 173 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.17% of CLYM.
The largest institutional holders are RA Capital Management, L.P. (17.25%), FMR, LLC (15.78%) and UBS Group AG (7.64%). Together, the top 10 institutions control 70.6% of shares outstanding. In their latest filings, 7 of the top 10 institutions increased their CLYM positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of CLYM
| Institution | Shares | % Held | Change |
|---|---|---|---|
| RA Capital Management, L.P. | 10.13M | 17.25% | -10.4% |
| FMR, LLC | 9.27M | 15.78% | +36.5% |
| UBS Group AG | 4.49M | 7.64% | +31.9% |
| Blackrock Inc. | 2.94M | 5.00% | +24.7% |
| Braidwell LP | 2.86M | 4.87% | +2.4% |
| Woodline Partners LP | 2.73M | 4.65% | +72.6% |
| Price (T.Rowe) Associates Inc | 2.42M | 4.12% | +13.7% |
| Vanguard Capital Management LLC | 2.38M | 4.04% | +39.9% |
| Adage Capital Partners GP L.L.C. | 2.17M | 3.69% | -13.5% |
| Cormorant Asset Management, LP | 2.11M | 3.59% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of CLYM
| Fund | Shares | % Held |
|---|---|---|
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.88M | 3.21% |
| T. Rowe Price Health Sciences Fund, Inc. | 1.64M | 2.79% |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 1.53M | 2.60% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.37M | 2.33% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.08M | 1.83% |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 996.40K | 1.70% |
| Fidelity Securities Fund-Fidelity Small Cap Growth K6 Fund | 977.59K | 1.66% |
| iShares Trust-iShares Russell 2000 ETF | 959.32K | 1.63% |
| Fidelity Securities Fund-Fidelity Series Small Cap Opportunities Fund | 876.30K | 1.49% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 721.30K | 1.23% |
Frequently asked questions
Who is the largest shareholder of Climb Bio?
RA Capital Management, L.P. is the largest institutional shareholder of CLYM, owning 17.25% of shares outstanding (10.13M shares) as of its latest 13F filing.
What percentage of Climb Bio is owned by institutions?
Institutions own about 117.9% of CLYM shares and 118.2% of the public float.
How much of Climb Bio do insiders own?
Insiders, such as officers and directors, own about 0.17% of CLYM shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.